How Much Is Zepbound With Insurance in 2026? Real Copays, Plan Scenarios, and the Savings Card

Key Takeaways

• With commercial insurance that covers Zepbound, monthly copays usually fall between $25 and $650, depending on tier, deductible status, and prior authorization rules.
• The Lilly Zepbound Savings Card can reduce eligible commercial copays to as little as $25 per fill (up to a per-fill cap), but it excludes Medicare, Medicaid, TRICARE, and VA enrollees.
• Many employer plans still exclude anti-obesity medications from coverage. A 2024 IFEBP survey found 57% of large employers covered GLP-1s for obesity, up from 41% the year before.
• Cash price at most retail pharmacies runs $1,060 to $1,300 a month for any Zepbound dose, before manufacturer self-pay vials or telehealth alternatives.
• If your plan denies Zepbound, three avenues recover cost: prior authorization with documented obesity criteria, the Lilly self-pay vial program, or compounded tirzepatide through a licensed pharmacy.

Direct answer (40-60 words)

With insurance that covers Zepbound, most patients pay $25 to $650 a month in 2026. The Lilly Zepbound Savings Card brings eligible commercial copays as low as $25 per fill. Without coverage, retail cash price runs $1,060 to $1,300, and Lilly's self-pay vials sit around $349 to $499.

Table of contents

1. The 30-second answer
2. Why your specific Zepbound copay varies so much
3. Six real plan scenarios
4. The Lilly Zepbound Savings Card explained
5. Prior authorization: what plans look for
6. Cash and self-pay vial pricing
7. Medicare, Medicaid, and TRICARE rules
8. Employer coverage trends in 2026
9. The compounded tirzepatide backup
10. How to verify your exact cost in 5 minutes
11. FAQ
12. Sources

Why your specific Zepbound copay varies so much

Zepbound is a brand-name injectable, so its cost is set by your insurance plan's pricing rules, not by the pharmacy. Two patients filling the same dose at the same store can pay very different amounts. Four variables drive the number on your receipt.

Your formulary tier. Insurance plans sort drugs into tiers. Zepbound usually lands on Tier 3 (non-preferred brand) or Tier 4 (specialty). Tier 3 copays run $50 to $150 per fill on most plans. Tier 4 typically uses coinsurance instead of flat copays, which means you pay a percentage (often 25% to 40%) of the negotiated price.

Your deductible status. High-deductible plans require you to spend a set amount out of pocket before cost-sharing begins. If your deductible is $3,500 and you've spent $0, your first Zepbound fill is the full negotiated rate (often $900 to $1,100). After you meet the deductible, the lower copay applies.

Prior authorization (PA). Most plans require your provider to submit clinical documentation showing medical necessity. This usually means a body mass index of 30+ (or 27+ with at least one weight-related comorbidity), prior weight-loss attempts, and sometimes proof you tried other therapies first. Without PA approval, you pay full cash price.

Whether your plan covers anti-obesity medications at all. Some employer self-funded plans flat-out exclude weight-loss drugs. In that case, no copay schedule applies because the drug isn't covered. You'd pay cash, use a savings card without insurance, or look at alternatives.

A 2024 KFF analysis (Cubanski et al., KFF 2024) found that even among plans listing Zepbound on their formulary, 78% required prior authorization and 31% added quantity limits.

Six real plan scenarios

These scenarios are anonymized composites built from typical FormBlends patient data and publicly disclosed plan formularies as of Q1 2026.

Scenario 1: Large employer PPO with anti-obesity coverage. A patient has a Blue Cross PPO through a Fortune 500 employer that opted into GLP-1 obesity coverage. Zepbound sits on Tier 3 with a $50 copay after deductible. Deductible is $1,000 and gets met by March. Pays $50 a month from April through December.

Scenario 2: Marketplace silver plan, prior auth approved. A patient on a marketplace silver plan with $4,200 deductible and 30% coinsurance after deductible. Zepbound's negotiated price is $1,025. Coinsurance is roughly $308 per fill once the deductible is met. Until then, full $1,025 per fill.

Scenario 3: HDHP without weight-loss coverage. A patient's high-deductible plan excludes anti-obesity medications. The plan denies Zepbound. The patient uses the Lilly self-pay vial program at roughly $499 a month, or switches to compounded tirzepatide.

Scenario 4: Marketplace plan with Lilly Savings Card. A patient on a marketplace bronze plan with a $200 Tier 3 copay applies the Lilly Zepbound Savings Card. The card reduces the copay to $25 per fill, up to the program's monthly cap and 13-fill annual limit.

Scenario 5: Medicare Advantage Part D enrollee. A 68-year-old retiree on Medicare Advantage. The plan covers Zepbound only for the new obstructive sleep apnea indication, not for weight loss alone. Without a sleep apnea diagnosis, the plan denies the prescription. Medicare patients aren't eligible for the Lilly Savings Card.

Scenario 6: Self-funded employer with carve-out PBM. A patient's employer carved out pharmacy benefits to a separate PBM that excluded Zepbound entirely. The patient appeals through the employer's HR benefits committee, files documentation of comorbid hypertension and prediabetes, and gets a one-year exception approved with a $75 copay.

The shared lesson across all six: the answer to "how much is Zepbound with insurance" is whatever your plan's specific rules say it is. There's no national price tag.

The Lilly Zepbound Savings Card explained

The Zepbound Savings Card is Eli Lilly's manufacturer copay assistance program. It's the single biggest cost reducer for patients with commercial insurance.

Eligibility:

• Commercial insurance that covers Zepbound (any copay amount)
• U.S. resident over 18
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or other government healthcare programs
• Prescription written for an FDA-approved indication

What it does:

• Reduces eligible commercial copays to as little as $25 per fill
• Per-fill maximum benefit applies (Lilly's published cap is $469 per monthly fill as of 2026)
• 13-fill annual limit
• Can be combined with insurance, but not with other discount programs at the same time

Who it doesn't help:

• Anyone with government coverage of any kind, including Medicare Advantage and Tricare
• Anyone whose plan flat-out excludes Zepbound (the card lowers a copay, it doesn't create coverage)
• Cash patients without any insurance (but Lilly's self-pay vial program is a separate option for them)

How to use it:

• Activate the card on Lilly's Zepbound website or grab a physical card from your provider
• Present alongside your insurance card at the pharmacy
• The pharmacist runs your insurance first, then applies the card to lower the copay

About 1 in 4 commercially insured Zepbound patients use the savings card based on Lilly's quarterly investor disclosures.

Prior authorization: what plans look for

A 2024 GoodRx analysis (GoodRx 2024) found that 64% of new GLP-1 prescriptions for obesity required prior authorization, and 38% of those PAs were denied on first submission. Knowing what plans look for shortens the approval cycle.

Documentation that helps approval:

• BMI of 30+ (or 27+ with at least one comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Documented attempts at lifestyle modification (often 6 months of supervised diet and exercise)
• Comorbidity diagnosis codes in the chart (ICD-10 E66.01 for obesity, plus comorbidity codes)
• Failed prior pharmacotherapy in some plans (older anti-obesity drugs or other GLP-1s)
• Provider attestation of medical necessity

Common denial reasons:

• BMI not documented or below threshold
• No documented lifestyle attempts
• Off-label use (cosmetic weight loss without comorbidities)
• Step therapy not completed (plan requires trying a cheaper alternative first)
• Quantity limit exceeded

Appeals process: If your PA is denied, you have the right to appeal. Most plans require the appeal within 60 to 180 days. Successful appeals typically include a peer-to-peer call between your prescriber and the plan's medical director, plus additional documentation. About 50% of first-level appeals succeed when the documentation is strong.

The American Medical Association's 2023 prior authorization survey reported that 94% of physicians reported PAs caused care delays, and 89% reported patients abandoning treatment because of PA hassle (AMA 2023).

Cash and self-pay vial pricing

Without insurance, you have three retail options.

Standard pharmacy cash price. Walmart, CVS, Walgreens, and the major retail chains charge $1,060 to $1,300 per fill for any Zepbound dose. The pen format and dose strength don't change the price meaningfully because Lilly's wholesale acquisition cost is the same across doses.

GoodRx and similar discount cards. GoodRx coupons typically knock $50 to $150 off the cash price, putting you in the $950 to $1,200 range. GoodRx doesn't combine with insurance.

Lilly self-pay vials (Zepbound Self Pay Pharmacy program). In 2024, Lilly launched a direct self-pay program that ships single-dose vials at a discount: roughly $349 for 2.5 mg and $499 for 5 mg, 7.5 mg, and 10 mg as of 2026. The vials require drawing into a syringe rather than using the pen. They're shipped through Lilly Direct, an Amazon-fulfilled program for U.S. residents without insurance coverage of Zepbound.

The self-pay vial program changed the math significantly. Before 2024, an uninsured patient paid $1,000+ a month. Now $349 to $499 is achievable through Lilly's official channel.

Medicare, Medicaid, and TRICARE rules

Medicare. A 2003 federal statute (the Medicare Modernization Act) bars Part D from covering drugs used for weight loss. Medicare didn't cover Wegovy or Zepbound for obesity. In March 2024, the FDA approved Wegovy for cardiovascular risk reduction in patients with obesity and established cardiovascular disease, and CMS issued guidance allowing Part D coverage for that indication. In late 2024, Zepbound received FDA approval for obstructive sleep apnea in adults with obesity, opening a similar coverage path. As of 2026, Medicare Part D plans may cover Zepbound for moderate to severe OSA in adults with obesity, but not for weight loss alone (CMS 2024).

Medicaid. Coverage varies by state. As of 2026, roughly 14 state Medicaid programs cover GLP-1 medications for obesity with prior authorization. The remaining states cover them only for type 2 diabetes (which means Zepbound, indicated for weight loss and OSA, is harder to access through Medicaid than Mounjaro, indicated for diabetes). The Medicaid and CHIP Payment and Access Commission tracks state-by-state coverage (MACPAC 2024).

TRICARE. Active duty service members and dependents have coverage for Zepbound for FDA-approved indications, but tiered copays apply through TRICARE Pharmacy. Veterans Affairs has its own formulary and Zepbound is restricted to specific clinical criteria.

If you're on any government program, the Lilly Savings Card cannot help you. The substitutes are the self-pay vial program, manufacturer patient assistance (LillyCares), or compounded tirzepatide.

Employer coverage trends in 2026

Self-funded employer plans cover an estimated 65% of Americans with employer-sponsored insurance. These plans set their own GLP-1 coverage rules.

A 2024 International Foundation of Employee Benefit Plans survey (IFEBP 2024) found:

• 57% of large employers covered GLP-1s for obesity (up from 41% in 2023)
• 78% covered GLP-1s for type 2 diabetes
• 25% used cost-management tools like prior auth, step therapy, or BMI thresholds
• 12% added GLP-1-specific exclusions in 2024 due to budget pressure
• 8% offered coverage but required participation in a lifestyle program

If your employer doesn't cover Zepbound, the next steps are: ask HR if a wellness program tier exists, request a formal coverage exception with comorbidity documentation, or pursue alternatives.

The compounded tirzepatide backup

For patients without insurance coverage and who don't fit the self-pay vial program, compounded tirzepatide is a common alternative.

Pricing:

• FormBlends compounded tirzepatide: $279 to $399 per month at maintenance dose
• Other licensed compounding pharmacies: $250 to $499 per month

Important compliance points:

• Compounded tirzepatide is not FDA-approved
• It's prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription
• It requires a clinical evaluation through a licensed provider
• The FDA removed tirzepatide from its drug shortage list in late 2024, which restricts large-scale 503B outsourcing facility production. Patient-specific 503A compounding under a valid prescription remains legal in most states.
• Compounded products are not interchangeable with brand-name Zepbound

When the compounded path makes sense:

• Insurance excludes Zepbound entirely
• Cash price is unsustainable and the self-pay vial program isn't enough
• You need predictable monthly cost

When brand-name Zepbound makes more sense:

• Insurance covers it with a copay under $100
• The Lilly Savings Card brings copays to $25
• You qualify for LillyCares patient assistance

A licensed clinician should walk through the trade-offs before either option starts.

How to verify your exact cost in 5 minutes

Step 1. Pull up your plan's drug formulary. Most insurer member portals have a "find a drug" tool. Search "tirzepatide" or "Zepbound."

Step 2. Note the tier and any restrictions (PA, step therapy, quantity limits).

Step 3. Run a test claim at your pharmacy. Bring your insurance card. Ask the pharmacist to "process a test claim" for Zepbound 5 mg. They'll quote your exact copay before you fill.

Step 4. Apply the Lilly Zepbound Savings Card if you have commercial insurance. Activate it on Lilly's site, present at the pharmacy, and ask the pharmacist to run both together.

Step 5. If the price isn't workable, use the same call to ask about Lilly self-pay vials or get a quote from a compounded telehealth platform.

This 5-minute verification prevents the most common cost surprise (a $400 copay you weren't expecting), and it identifies whether to pursue PA, savings card, or alternative paths.

FAQ

How much is Zepbound with insurance per month? Most patients pay $25 to $650 per month with commercial insurance, depending on formulary tier, deductible status, and prior authorization. The Lilly Zepbound Savings Card can lower eligible copays to as little as $25 per fill.

Does insurance cover Zepbound for weight loss in 2026? About 57% of large employer plans cover Zepbound for obesity, per IFEBP's 2024 survey. Marketplace plan coverage varies. Medicare doesn't cover Zepbound for weight loss alone but does cover it for moderate to severe obstructive sleep apnea in adults with obesity.

What is the Zepbound Savings Card and who qualifies? The Lilly Zepbound Savings Card is a manufacturer copay assistance program for commercially insured patients. It can reduce copays to as little as $25 per fill, up to a per-fill cap and a 13-fill annual limit. Medicare, Medicaid, TRICARE, and VA enrollees are excluded.

How much does Zepbound cost without insurance? Cash price at major retail pharmacies runs $1,060 to $1,300 per fill. Lilly's self-pay vial program offers single-dose vials at $349 (2.5 mg) and roughly $499 (5 mg, 7.5 mg, 10 mg) shipped through Lilly Direct.

Will Medicare cover Zepbound? Medicare Part D plans may cover Zepbound for adults with obesity who have moderate to severe obstructive sleep apnea, following the late 2024 FDA indication and CMS guidance. Medicare still does not cover Zepbound for weight loss alone.

Why was my Zepbound prior authorization denied? The most common reasons are missing BMI documentation, no documented lifestyle modification attempts, plan exclusion of anti-obesity medications, or step therapy requirements that haven't been completed. About 50% of first-level appeals succeed with stronger documentation.

How do I appeal a Zepbound denial? Submit a written appeal within your plan's deadline (usually 60 to 180 days). Include updated BMI, comorbidity documentation, history of prior weight-loss attempts, and a letter of medical necessity from your prescriber. A peer-to-peer call between your provider and the plan's medical director often helps.

Is compounded tirzepatide cheaper than Zepbound? For uninsured patients or those whose plans exclude Zepbound, yes. Compounded tirzepatide typically runs $279 to $499 per month, against cash retail price of $1,060+. For insured patients with low copays after the savings card, brand-name Zepbound may be similar or cheaper.

Does the Zepbound Savings Card work at any pharmacy? The card works at most major retail and mail-order pharmacies in the U.S. that accept manufacturer copay assistance. It does not work for prescriptions paid through Medicare, Medicaid, TRICARE, or VA.

Can I use GoodRx with my insurance for Zepbound? You can use either GoodRx or insurance, but not both for the same fill. If GoodRx's cash price is lower than your insurance copay, you can choose to pay GoodRx instead. The GoodRx payment doesn't count toward your deductible.

What is Lilly Direct and Lilly self-pay? Lilly Direct is Eli Lilly's online platform that ships Zepbound vials directly to U.S. patients without insurance coverage of the medication. Pricing is roughly $349 for 2.5 mg vials and around $499 for 5 mg, 7.5 mg, and 10 mg as of 2026.

Does my employer have to cover Zepbound? No. The Affordable Care Act doesn't require employer plans to cover anti-obesity medications, and most self-funded plans set their own rules. Some employers add Zepbound coverage as a wellness benefit, others exclude it. HR can confirm.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
2. Cubanski J, Neuman T. Medicare Part D and weight-loss drugs. KFF analysis. 2024.
3. International Foundation of Employee Benefit Plans. GLP-1 drug coverage trends in employer plans. IFEBP Survey. 2024.
4. American Medical Association. 2023 AMA prior authorization physician survey. AMA. 2023.
5. GoodRx Research. Prior authorization rates for GLP-1 weight-loss medications. GoodRx. 2024.
6. Centers for Medicare and Medicaid Services. Part D coverage of anti-obesity medications: guidance memo. CMS. 2024.
7. Eli Lilly and Company. Zepbound prescribing information. Indianapolis, IN: Lilly USA. Rev. 2024.
8. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. FDA News Release. December 2024.
9. Eli Lilly and Company. Zepbound self-pay vials and Lilly Direct fulfillment. Lilly press materials. 2024.
10. Medicaid and CHIP Payment and Access Commission. State Medicaid coverage of obesity treatments. MACPAC. 2024.
11. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for overweight and obesity. NIDDK. 2023.
12. Garvey WT, et al. Tirzepatide for chronic weight management. SURMOUNT-2 trial. Lancet. 2023;402:613-626.
13. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea. SURMOUNT-OSA. N Engl J Med. 2024;391:1193-1205.
14. U.S. Food and Drug Administration. Updated FDA guidance on compounded tirzepatide. FDA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Lilly Direct are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.